Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -100% Improvement Relative Risk Ventilation 57% Progression 53% Suzuki et al. Molnupiravir for COVID-19 EARLY Is early treatment with molnupiravir beneficial for COVID-19? PSM retrospective 920 patients in Japan Lower progression with molnupiravir (p=0.042) Suzuki et al., Clinical and Experimental Medicine, doi:10.1007/s10238-022-00949-3 Favors molnupiravir Favors control
Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Suzuki et al., Clinical and Experimental Medicine, doi:10.1007/s10238-022-00949-3 (date from earlier preprint)
Suzuki et al., Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus.., Clinical and Experimental Medicine, doi:10.1007/s10238-022-00949-3 (date from earlier preprint)
Oct 2022   Source   PDF  
  All Studies   Meta
Retrospective 1,921 patients in Japan, showing lower progression with molnupiravir use.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson,] for analysis of variants potentially created by molnupiravir.
risk of death, 100% higher, RR 2.00, p = 0.60, treatment 2 of 230 (0.9%), control 3 of 690 (0.4%), propensity score matching.
risk of mechanical ventilation, 57.1% lower, RR 0.43, p = 1.00, treatment 0 of 230 (0.0%), control 1 of 690 (0.1%), NNT 690, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), propensity score matching.
risk of progression, 53.0% lower, RR 0.47, p = 0.04, treatment 9 of 230 (3.9%), control 58 of 690 (8.4%), NNT 22, adjusted per study, odds ratio converted to relative risk, propensity score matching, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Suzuki et al., 5 Oct 2022, retrospective, Japan, peer-reviewed, 53 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Yasuhito Suzuki, Yoko Shibata, Hiroyuki Minemura, Takefumi Nikaido, Yoshinori Tanino, Atsuro Fukuhara, Ryuzo Kanno, Hiroyuki Saito, Shuzo Suzuki, Yayoi Inokoshi, Eiichiro Sando, Hirofumi Sakuma, Tatsuho Kobayashi, Hiroaki Kume, Masahiro Kamimoto, Hideko Aoki, Akira Takama, Taku Iizuka, Takamichi Kamiyama, Masaru Nakayama, Kiyoshi Saito, Koichi Tanigawa, Masahiko Sato, Yuichi Waragai, Toshiyuki Kambe, Norio Kanzaki, Teruhisa Azuma, Hiromasa Okamoto, Keiji Sakamoto, Yuichi Nakamura, Hiroshi Ohtani, Mitsuru Waragai, Shinsaku Maeda, Tokiya Ishida, Keishi Sugino, Wataru Abe, Yasuhiko Tsukada, Tomoyoshi Lee, Ryuki Yamada, Riko Sato, Takumi Onuma, Hikaru Tomita, Mikako Saito, Natsumi Watanabe, Mami Rikimaru, Takaya Kawamata, Julia Morimoto, Ryuichi Togawa, Yuki Sato, Junpei Saito, Kenya Kanazawa, Sugihiro Hamaguchi, Ken Iseki
Clinical and Experimental Medicine, doi:10.1007/s10238-022-00949-3
It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We here evaluated the efficacy of molnupiravir in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron variant surge in Fukushima Prefecture, Japan. We enrolled patients with mild-to-moderate COVID-19 who were admitted to hospitals between January and April, 2022. Clinical deterioration after admission was compared between molnupiravir users (n = 230) and non-users (n = 690) after 1:3 propensity score matching. Additionally, we performed forward stepwise multivariate logistic regression analysis to evaluate the association between clinical deterioration after admission and molnupiravir treatment in the 1:3 propensity score-matched subjects. The characteristics of participants in both groups were balanced as indicated by covariates with a standardized mean difference of < 0.1. Regarding comorbidities, there was no imbalance between the two groups, except for the presence of hypertension, dyslipidemia, diabetes mellitus, and cardiac disease. The clinical deterioration rate was significantly lower in the molnupiravir users compared to the non-users (3.90% vs 8.40%; P = 0.034). Multivariate logistic regression analysis demonstrated that receiving molnupiravir was a factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.206-0.973; P = 0.042), independent of other covariates. This real-world study demonstrates that molnupiravir contributes to the prevention of deterioration in COVID-19 patients after hospitalization during the Omicron variant phase. Keywords Molnupiravir • COVID-19 • Omicron variant • Real-world • Effectiveness Abbreviations CI Confidence interval CKD Chronic kidney disease COVID-19 Coronavirus disease 2019 CRP C-reactive protein CT Computed tomography ECMO Extracorporeal membrane oxygenation IPTW Inverse probability of treatment weighting LDH Lactate dehydrogenase OR Odds ratio SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 SMD Standardized mean difference * Yoko Shibata
Author contribution Conception and design: YS and YS. Analysis and drafting the manuscript: YS and YS. Data curation: all authors. Final approval of the manuscript: all authors. Declarations Conflict of interest Y Shibata and H Minemura received lecture fees and research grants from Chugai Pharmaceutical Co., Ltd. Y Shibata and J Saito received lecture fees from GlaxoSmithKline K.K. The other authors report no conflicts of interest related to this study. Ethic approval This study was performed in line with the principles of the Declaration of Helsinki. The protocol was approved by the local ethical committee. Consent to publication The authors have seen the final version of the manuscript and approved submission for publication. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the..
Atmosudigdo, Lim, Radi, dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression, Clin Med Insights Endocrinol Diabetes, doi:10.1177/1179551421990675
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharm Stat, doi:10.1002/pst.433
Austin, Stuart, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies, Stat Med
Bernal, Da Silva, Musungaie, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med, doi:10.1056/NEJMoa2116044
Bojkova, Widera, Ciesek, Wass, Michaelis et al., Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates, Cell Res, doi:10.1038/s41422-022-00619-9
Callaway, Heavily mutated Omicron variant puts scientists on alert, Nature, doi:10.1038/d41586-021-03552-w
Gupta, Gonzalez-Rojas, Juarez, Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2022.2832
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Hoffmann, Krüger, Schulz, The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic, Cell, doi:10.1016/j.cell.2021.12.032
Korber, Fischer, Gnanakaran, Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus, Cell, doi:10.1016/j.cell.2020.06.043
Liu, Rocklöv, The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta, J Travel Med, doi:10.1093/jtm/taac037
Ohashi, Hishiki, Akazawa, Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, Antiviral Res, doi:10.1016/j.antiviral.2022.105372
Peng, He, Xue, Yang, Liu et al., Role of Hypertension on the Severity of COVID-19: A Review, J Cardiovasc Pharmacol
Polack, Thomas, Kitchin, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med, doi:10.1056/NEJMoa2034577
Ren, Nishimura, Tjan, Large-scale serosurveillance of COVID-19 in Japan: acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak, PLoS ONE, doi:10.1371/journal.pone.0266270
Rosenke, Okumura, Lewis, MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model, doi:10.1101/2022.02.22.481491v1
Shiba, Kawahara, using propensity scores for causal inference: pitfalls and tips, J Epidemiol, doi:10.2188/jea.JE20210145
Shibata, Minemura, Suzuki, Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19, doi:10.1101/2021.12.13.21267698v1
Takashita, Kinoshita, Yamayoshi, Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2, N Engl J Med, doi:10.1056/NEJMc2201933
Vanblargan, Errico, Halfmann, An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies, Nat Med, doi:10.1038/s41591-021-01678-y
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2035002
Wong, Au, Lau, Cowling, Leung, Realworld effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study, Lancet Infect Dis, doi:10.1016/S1473-3099(22)00507-2
Yamamoto, Wada, Ichikawa, Evaluation of biomarkers of severity in patients with COVID-19 infection, J Clin Med, doi:10.3390/jcm10173775
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop